Ardelyx Inc

Ardelyx, Inc. innovates in biotech by targeting gastrointestinal transporters to treat mineral metabolism disorders, driving new therapies and improving patient outcomes.

Ardelyx’s IBS‑C study accepted for Digestive Disease Week 2026 poster; shares hit a 200‑day low, while analyst ratings hover around “Moderate Buy.

Ardelyx’s new partnership and promising preclinical data signal a boost for its mineral‑metabolism drugs, while disciplined capital strategy keeps investors focused on long‑term growth.

Ardelyx’s latest SEC filing reveals CMO stock‑unit details amid a dynamic biotech market, spotlighting its focus on innovative metabolic disorder therapies.

Ardelyx, Inc. develops gut‑targeted drugs for mineral‑metabolism disorders and trades on Nasdaq with a $1.46 bn market cap, offering insight into its biotech strategy and insider holdings.

Ardelyx, Inc. drives biotech innovation by targeting gastrointestinal transporters to correct mineral metabolism disorders, offering a unique therapeutic pipeline amid market volatility.

Ardelyx Inc. leads biotech with targeted GI tract drugs correcting mineral metabolism, while navigating growth challenges—discover its latest therapies and market outlook.

Ardelyx’s latest earnings reveal a biotech firm focused on GI‑centric metabolic drugs, trading at $5.73 with a $1.41B market cap and high investor confidence.

Ardelyx’s Q4 results show a revenue beat but earnings miss, hurting stock despite a $1 billion 2029 goal for Ibsrela and new pipeline expansion.

Ardelyx’s new Tenapanor patent boosts its biotech pipeline, targeting mineral‑metabolism disorders and enhancing investor confidence.